Literature DB >> 9199746

Macula toxicity after intravitreal amikacin.

A A Seawright1, R D Bourke, R J Cooling.   

Abstract

BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.
METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.
RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.
CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia. Treatment strategies aimed at avoiding retinal toxicity are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9199746     DOI: 10.1111/j.1442-9071.1996.tb01569.x

Source DB:  PubMed          Journal:  Aust N Z J Ophthalmol        ISSN: 0814-9763


  9 in total

1.  Macular infarction after intravitreal amikacin: mounting evidence against amikacin.

Authors:  G Galloway; A Ramsay; K Jordan; A Vivian
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

2.  Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.

Authors:  Sophie Lefèvre; Maher Saleh; Luc Marcellin; Audrey Subilia; Tristan Bourcier; Gilles Prévost; François Jehl
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

3.  Safety of intravitreal quinupristin/dalfopristin in an animal model.

Authors:  Veronica E Giordano; Sergio E Hernandez-Da Mota; Tania N Adabache-Guel; Armando Castillejos-Chevez; Sonia Corredor-Casas; Samantha M Salinas-Longoria; Rafael Romero-Vera; Juan M Jimenez-Sierra; Jose L Guerrero-Naranjo; Virgilio Morales-Canton
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

4.  Susceptibility of bacterial isolates to vancomycin and ceftazidime from patients with endophthalmitis: Is there a need to change the empirical therapy in suspected bacterial endophthalmitis?

Authors:  Ashok Kumar Reddy; Raja Rami Reddy; Muralidhar Rao Paruvelli; Srinivas Ambatipudi; Alka Rani; Sikander A K Lodhi; Juturi Maruthi Lokabhi Reddy; K Ramakanth Reddy; Niraj Pandey; Rituraj Videkar; Manish Kumar Sinha; Ajit Babu Majji; Nilanjana Deb-Jorder; Atul Kumar Sahu; Jyostna Myneni; Anina Abraham
Journal:  Int Ophthalmol       Date:  2014-11-11       Impact factor: 2.031

5.  Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis.

Authors:  I M Gan; J T van Dissel; W H Beekhuis; W Swart; J C van Meurs
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

6.  Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives.

Authors:  M Kernt; A Kampik
Journal:  Clin Ophthalmol       Date:  2010-03-24

7.  A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results.

Authors:  Eric W Lindstedt; Carlien A Bennebroek; Dymph J van der Werf; Marc Veckeneer; Annette Ossewaarde-van Norel; Chris C Mayland Nielsen; Rene J Wubbels; Jaap T van Dissel; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-10       Impact factor: 3.117

8.  Atrophy of retinal inner layers is associated with poor vision after endophthalmitis: a spectral domain optical coherence tomography study.

Authors:  X Lu; W Chen; H Xia; K Zheng; C Jin; D S C Ng; H Chen
Journal:  Eye (Lond)       Date:  2017-06-02       Impact factor: 3.775

9.  Macular ischemia after intravitreal amikacin on patient with intraocular foreign body.

Authors:  Arief Kartasasmita; Susi Mona; Erwin Iskandar; Iwan Sovani; Djonggi Panggabean
Journal:  GMS Ophthalmol Cases       Date:  2017-03-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.